The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma

Annals of Oncology

Volumn 23, Issue 4, 2012, Pages 961-967

  Erculj N ^a   Kovac V ^b   Hmeljak, J ^c   Dolzan V ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

^c UNIVERSITY OF PRIMORSKA   (Slovenia)

Author keywords

DNA repair polymorphisms; Glutathione S transferases; Malignant mesothelioma; Pharmacogenetics; Platinum

Indexed keywords

DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; PEMETREXED; PLATINUM COMPLEX; VINCRISTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ERCC1 GENE; EXCISION REPAIR; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GLUTATHIONE S TRANSFERASE GENE; HAPLOTYPE; HUMAN; KIDNEY DISEASE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; NAUSEA; ONCOGENE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; THROMBOCYTOPENIA; WILD TYPE; XPD GENE;

ADULT; AGED; AGED, 80 AND OVER; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DISEASE-FREE SURVIVAL; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENETIC ASSOCIATION STUDIES; GLUTATHIONE TRANSFERASE; HAPLOTYPES; HUMANS; LEUKOPENIA; MALE; MESOTHELIOMA; MIDDLE AGED; NAUSEA; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; SEQUENCE ANALYSIS, DNA; THROMBOCYTOPENIA; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84859514200     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr324     Document Type: Article

References (49)

1. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960; 17: 260-271.
2. Hodgson JT, McElvenny DM, Darnton AJ et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005; 92: 587-593.
3. Dodic Fikfak M, Franko A. Predicted incidence of mesothelioma in Slovenia. In Proceedings of the European Conference on Asbestos Risk and Management, Rome, Italy. Rome: ISPESL 2006; 43-46.
4. Scherpereel A, Astoul P, Baas P et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 35: 479-495.
5. Krug LM, Pass HI, Rusch VW et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 3007-3013.
6. Berghmans T, Paesmans M, Lalami Y et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002; 38: 111-121.
7. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
8. Lee CW, Murray N, Anderson H et al. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 2009; 64: 308-313.
9. Wolfe KJ, Wickliffe JK, Hill CE et al. Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet Genomics 2007; 17: 897-905.
10. Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003; 111: 1843-1850.
11. Lunn RM, Helzlsouer KJ, Parshad R et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000; 21: 551-555.
12. Johnson SW, Swiggard PA, Handel LM et al. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res 1994; 54: 5911-5916.
13. Vergote I, Calvert H, Kania M et al. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer 2009; 45: 1415-1423.
14. Langie SA, Wilms LC, Hamalainen S et al. Modulation of nucleotide excision repair in human lymphocytes by genetic and dietary factors. Br J Nutr 2009; 103: 490-501.
15. Shen J, Desai M, Agrawal M et al. Polymorphisms in nucleotide excision repair genes and DNA repair capacity phenotype in sisters discordant for breast cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 1614-1619.
16. Cullen KJ, Newkirk KA, Schumaker LM et al. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res 2003; 63: 8097-8102.
17. Ekhart C, Rodenhuis S, Smits PH et al. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat Rev 2009; 35: 18-31.
18. Ali-Osman F, Akande O, Antoun G et al. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione Stransferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997; 272: 10004-10012.
19. Watson MA, Stewart RK, Smith GB et al. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19: 275-280.
20. Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000; 61: 154-166.
21. Gurubhagavatula S, Liu G, Park S et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22: 2594-2601.
22. Okuda K, Sasaki H, Hikosaka Y et al. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer. J Surg Res 2011; 168: 206-212.
23. Zhou W, Gurubhagavatula S, Liu G et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10: 4939-4943.
24. Park DJ, Stoehlmacher J, Zhang W et al. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61: 8654-8658.
25. Stoehlmacher J, Park DJ, Zhang W et al. Association between glutathione Stransferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94: 936-942.
26. Kim HS, Kim MK, Chung HH et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol 2009; 113: 264-269.
27. Caronia D, Patino-Garcia A, Milne RL et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 2009; 9: 347-353.
28. Bradbury PA, Kulke MH, Heist RS et al. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics 2009; 19: 613-625.
29. Kraggerud SM, Oldenburg J, Alnaes GI et al. Functional glutathione S-transferase genotypes among testicular germ cell tumor survivors: associations with primary and post-chemotherapy tumor histology. Pharmacogenet Genomics 2009; 19: 751-759.
30. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15: 257-260.
31. Hmeljak J, Kern I, Cor A. No implication of Simian virus 40 in pathogenesis of malignant pleural mesothelioma in Slovenia. Tumori 2010; 96: 667-673.
32. Bohanec Grabar P, Logar D, Tomsic M et al. Genetic polymorphisms of glutathione S-transferases and disease activity of rheumatoid arthritis. Clin Exp Rheumatol 2009; 27: 229-236.
33. Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 2007; 23: 1038-1039.
34. Tregouet DA, Tiret L. Cox proportional hazards survival regression in haplotypebased association analysis using the Stochastic-EM algorithm. Eur J Hum Genet 2004; 12: 971-974.
35. Fennell DA, Gaudino G, O'Byrne KJ et al. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008; 5: 136-147.
36. Zucali PA, Giovannetti E, Destro A et al. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clin Cancer Res 2011; 17: 2581-2590.
37. Stoehlmacher J, Park DJ, Zhang W et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91: 344-354.
38. Li F, Sun X, Sun N et al. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol 2010; 33: 489-494.
39. Seo BG, Kwon HC, Oh SY et al. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. Oncol Rep 2009; 22: 127-136.
40. Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 2009; 10: 54-61.
41. Suk R, Gurubhagavatula S, Park S et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 2005; 11: 1534-1538.
42. Borel C, Deutsch S, Letourneau A et al. Identification of cis- and trans-regulatory variation modulating microRNA expression levels in human fibroblasts. Genome Res 2010; 21: 68-73.
43. Lecomte T, Landi B, Beaune P et al. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006; 12: 3050-3056.
44. Moyer AM, Sun Z, Batzler AJ et al. Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy. Cancer Epidemiol Biomarkers Prev 2010; 19: 811-821.
45. Muers MF, Stephens RJ, Fisher P et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371: 1685-1694.
46. Mort R, Mo L, McEwan C, Melton DW. Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. Br J Cancer 2003; 89: 333-337.
47. Marsh S, Mallon MA, Goodfellow P, McLeod HL. Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. Pharmacogenomics 2005; 6: 873-877.
48. Weiss JR, Baer MR, Ambrosone CB et al. Concordance of pharmacogenetic polymorphisms in tumor and germ line DNA in adult patients with acute myeloid leukemia. Cancer Epidemiol Biomarkers Prev 2007; 16: 1038-1041.
49. Vidan-Jeras B, Jurca B, Dolzan V et al. Slovenian Caucasian normal. In Terasaki PI, Gjertson DW (eds), HLA 1998. Lenexa, KS: American Society for Histocompatibility and Immunogenetics 1998; 180-181.